Patrick Waller

Summary

Country: UK

Publications

  1. pmc Drug safety and the media
    Patrick C Waller
    Br J Clin Pharmacol 61:123-6. 2006
  2. ncbi request reprint European commission consultation on pharmacovigilance
    Patrick Waller
    Pharmacoepidemiol Drug Saf 17:108-9. 2008
  3. doi request reprint Developing tools for the safety specification in risk management plans: lessons learned from a pilot project
    Andrew J P Cooper
    GlaxoSmithKline GSK Ltd, Greenford, Middlesex, UK
    Pharmacoepidemiol Drug Saf 17:445-54. 2008
  4. ncbi request reprint A model for the future conduct of pharmacovigilance
    Patrick C Waller
    Post Licensing Division, Medicines Control Agency, London, UK
    Pharmacoepidemiol Drug Saf 12:17-29. 2003
  5. ncbi request reprint Making the most of spontaneous adverse drug reaction reporting
    Patrick C Waller
    Consultant in Pharmacoepidemiology, Southampton, UK
    Basic Clin Pharmacol Toxicol 98:320-3. 2006
  6. ncbi request reprint Impact analysis of signals detected from spontaneous adverse drug reaction reporting data
    Patrick Waller
    Patrick Waller Limited, Consultancy in Pharmacovigilance and Pharmacoepidemiology, Southampton, UK
    Drug Saf 28:843-50. 2005
  7. pmc Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database
    Patrick Waller
    Drug Safety Research Unit, Southampton, UK
    Br J Clin Pharmacol 59:213-9. 2005
  8. ncbi request reprint Dealing with uncertainty in drug safety: lessons for the future from sertindole
    Patrick Waller
    Pharmacoepidemiol Drug Saf 12:283-7; discussion 289-90. 2003
  9. ncbi request reprint Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency
    Suzie Seabroke
    Pharmacoepidemiology Unit, Vigilance and Risk Management of Medicines, Medicines and Healthcare products Regulatory Agency, 151 Buckingham Palace Road, London, SW1W 9SZ, UK
    Drug Saf 36:1025-32. 2013
  10. pmc Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions
    Paul Barrow
    Post Licensing Division, Medicines and Healthcare products Regulatory Agency, London, UK
    Br J Clin Pharmacol 61:233-7. 2006

Collaborators

Detail Information

Publications13

  1. pmc Drug safety and the media
    Patrick C Waller
    Br J Clin Pharmacol 61:123-6. 2006
    ..In order to promote more balanced coverage and avoid unnecessary scares, professionals working in the area of drug safety should rethink their strategies for dealing with the media...
  2. ncbi request reprint European commission consultation on pharmacovigilance
    Patrick Waller
    Pharmacoepidemiol Drug Saf 17:108-9. 2008
  3. doi request reprint Developing tools for the safety specification in risk management plans: lessons learned from a pilot project
    Andrew J P Cooper
    GlaxoSmithKline GSK Ltd, Greenford, Middlesex, UK
    Pharmacoepidemiol Drug Saf 17:445-54. 2008
    ..A collaborative research project was conducted to gain experience with tools for presenting and evaluating data in the safety specification. This paper presents those tools found to be useful and the lessons learned from their use...
  4. ncbi request reprint A model for the future conduct of pharmacovigilance
    Patrick C Waller
    Post Licensing Division, Medicines Control Agency, London, UK
    Pharmacoepidemiol Drug Saf 12:17-29. 2003
    ..Although the vision is holistic, it would be possible to test and implement parts of the model in a piecemeal fashion...
  5. ncbi request reprint Making the most of spontaneous adverse drug reaction reporting
    Patrick C Waller
    Consultant in Pharmacoepidemiology, Southampton, UK
    Basic Clin Pharmacol Toxicol 98:320-3. 2006
    ..However much it can be improved, spontaneous adverse drug reaction reporting is unlikely to identify all important unrecognized drug safety hazards. Complementary approaches therefore still need to be identified and developed...
  6. ncbi request reprint Impact analysis of signals detected from spontaneous adverse drug reaction reporting data
    Patrick Waller
    Patrick Waller Limited, Consultancy in Pharmacovigilance and Pharmacoepidemiology, Southampton, UK
    Drug Saf 28:843-50. 2005
    ..A computer program has been written to facilitate the process and reduce error. Further work is required to test the feasibility and value of impact analysis in practice...
  7. pmc Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database
    Patrick Waller
    Drug Safety Research Unit, Southampton, UK
    Br J Clin Pharmacol 59:213-9. 2005
    ....
  8. ncbi request reprint Dealing with uncertainty in drug safety: lessons for the future from sertindole
    Patrick Waller
    Pharmacoepidemiol Drug Saf 12:283-7; discussion 289-90. 2003
  9. ncbi request reprint Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency
    Suzie Seabroke
    Pharmacoepidemiology Unit, Vigilance and Risk Management of Medicines, Medicines and Healthcare products Regulatory Agency, 151 Buckingham Palace Road, London, SW1W 9SZ, UK
    Drug Saf 36:1025-32. 2013
    ..The prioritisation of drug safety issues for further evaluation or regulatory action is critical to ensure that acceptable timelines and appropriate resource allocation are defined to meet public health and regulatory obligations...
  10. pmc Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions
    Paul Barrow
    Post Licensing Division, Medicines and Healthcare products Regulatory Agency, London, UK
    Br J Clin Pharmacol 61:233-7. 2006
    ..To compare Hospital Episode Statistics for 'drug-related' admissions with spontaneously reported adverse drug reactions (ADRs) using UK Yellow Card data for the period 1996-2000...
  11. ncbi request reprint Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study
    Emma Heeley
    Post Licensing Division, Medicines and Healthcare products Regulatory Agency, London, UK
    Drug Saf 28:901-6. 2005
    ..This paper describes a pilot project whereby impact analysis was simultaneously introduced into practice in a regulatory setting and tested in comparison with the existing approach...
  12. ncbi request reprint An analysis of the exclusion criteria used in observational pharmacoepidemiological studies
    Michael Perrio
    Drug Safety Research Unit, Southampton, UK
    Pharmacoepidemiol Drug Saf 16:329-36. 2007
    ..The application of exclusion criteria in pharmacoepidemiological studies could have a major impact on the findings but there appears to have been no previous research to examine the types of exclusion criteria applied...
  13. pmc Drug safety and regulation
    Patrick C Waller
    BMJ 331:4-5. 2005